Locally advanced (unresectable) pancreatic cancer (LAPC) is surgically unresectable and often treated with chemotherapy. Most previous studies, that have evaluated conversion surgery after chemotherapy, included heterogeneous patients and chemotherapy regimens, making it challenging to determine the impact of FOLFIRINOX. The present study evaluated the survival benefit of conversion surgery in patients with LAPC who received FOLFIRINOX chemotherapy, and analyzed the prognostic factors.

中文翻译：

---

转化手术对接受 FOLFIRINOX 化疗的局部晚期胰腺癌患者生存期的影响

局部晚期（不可切除）胰腺癌 (LAPC) 无法通过手术切除，通常采用化疗进行治疗。之前评估化疗后转化手术的大多数研究包括异质性患者和化疗方案，这使得确定 FOLFIRINOX 的影响具有挑战性。本研究评估了接受 FOLFIRINOX 化疗的 LAPC 患者中转手术的生存获益，并分析了预后因素。